跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 854 条关于
“enfortumab-vedotin”
全部
854
临床试验
582
药物
44
机构
0
资讯
228
去年
Enfortumab Vedotin Plus Pembrolizumab Approved in Japan for Urothelial Carcinoma
2年前
European Commission Approves PADCEV™ (enfortumab vedotin) Plus KEYTRUDA® (pembrolizumab) for First-Line Advanced Urothelial Cancer
去年
Enfortumab Vedotin Plus Pembrolizumab Reshapes Bladder Cancer Treatment Landscape
2年前
Enfortumab Vedotin and Pembrolizumab Show Significant Survival Benefit in Urothelial Cancer Treatment
去年
Enfortumab Vedotin Shows Manageable Safety Profile in Ultra-Elderly Urothelial Cancer Patients
去年
Enfortumab Vedotin Shows Varied Efficacy Across Primary and Metastatic Urothelial Carcinoma Sites
9个月前
FDA Approves Enfortumab Vedotin Plus Pembrolizumab for Perioperative Treatment of Muscle-Invasive Bladder Cancer
去年
Adverse Events Linked to Better Survival Outcomes in Enfortumab Vedotin Treatment for Urothelial Cancer
2年前
Enfortumab Vedotin Shows Efficacy in Advanced Urothelial Carcinoma Outside Clinical Trials
去年
Enfortumab Vedotin Shows Promise for Upper Tract Urothelial Cancer Patients Ineligible for Standard Treatment
第 1 页,共 23 页
上一页
下一页